What we learnt from Temple & Webster, Cochlear and Pro Medicus’ results

News Snapshot:

Anthony Macdonald: Investors certainly aren’t going anywhere at Cochlear, which had a stonking year, and has issued strong guidance for 2024. Chief executive Dig Howitt said revenue in 2023 was better than expected thanks to market growth, market share gains, improved clinical capacity and more COVID-catch-up surgeries than expected. And to his credit, he was honest enough to say it was unlikely to be that way again in FY24 – the market loves an experienced chief executive not scared to be honest. One legacy from the good revenue year in FY23 is bonuses paid to the staff; revenue growth (above...